A commonly known steroid drug has been found to greatly improve survival for COVID-19 patients. In fact, among severe patients, the steroid, Dexamethasone, reduced the number of deaths by one-third in a study conducted by the University of Oxford.

The FDA has revoked its emergency use authorization for hydroxychloroquine as a treatment for COVID-19 hospital patients, determining that the controversial drug was “unlikely to be effective in treating COVID-19.”

The COVID-19 pandemic hit rural hospitals especially hard—and that’s bad news for patients in areas already associated with poor cardiovascular outcomes.

As the COVID-19 pandemic rages on, it is difficult to know just how many healthcare workers have lost their lives battling this deadly virus. According to a new project, the number currently sits at 586—and it is expected to continue rising.

The researchers explored data from orthotopic heart transplant patients who were hospitalized for COVID-19 at one of two facilities.

HHS is distributing another $35 billion from the CARES Act designated for healthcare providers responding to the crisis. The CARES Act allocated $175 billion in relief funds to hospitals and healthcare providers, especially those majorly affected by the pandemic.

Hypertension is associated with a much greater risk of dying from COVID-19, according to new research published in European Heart Journal. The study’s authors noted that outcomes improved if patients took antihypertensive medications as recommended.

The hospital is accused of listing an acute myocardial infarction as the cause of the patient’s death and not mentioning COVID-19 at all.